PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Grandl, G. ; Novikoff, A. ; Liu, X. ; Müller, T.D.

Recent achievements and future directions of anti-obesity medications.

Lancet Reg. Health-Eur. 47:101100 (2024)
Publ. Version/Full Text DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Pharmacological management of obesity long suffered from a reputation of a 'Mission Impossible,' with inefficient weight loss and/or unacceptable tolerability. However, the tide has turned with recent progress in biochemical engineering and the development of long-acting agonists at the receptor for glucagon-like peptide-1 (GLP-1), and with unimolecular peptides that simultaneously possess activity at the receptors for GLP-1, the glucose-dependent insulinotropic polypeptide (GIP) and glucagon. Some of these novel therapeutics not only improve body weight and glycemic control in individuals with obesity and type 2 diabetes with hitherto unmet efficacy and tolerable safety, but also exhibit potential therapeutic value in diverse areas such as neurodegenerative diseases, fatty liver disease, dyslipidemia, atherosclerosis, and cardiovascular diseases. In this review, we highlight recent advances in incretin-based therapies and discuss their pharmacological potential within and beyond the treatment of obesity and diabetes, as well as their limitations in use, side effects, and underlying molecular mechanisms.
Impact Factor
Scopus SNIP
Altmetric
13.600
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Anti-obesity Medication (aom) ; Diabetes ; Gip ; Glp-1 ; Obesity; Glucagon-like Peptide-1; Dependent Insulinotropic Polypeptide; Once-weekly Semaglutide; Glp-1 Receptor Agonist; Inhibits Bone-resorption; Double-blind; Cardiovascular Outcomes; Parallel-group; Body-weight; Open-label
Language english
Publication Year 2024
HGF-reported in Year 2024
ISSN (print) / ISBN 2666-7762
e-ISSN 2666-7762
Journal The Lancet Regional Health - Europe
Quellenangaben Volume: 47, Issue: , Pages: , Article Number: 101100 Supplement: ,
Publisher Elsevier
Publishing Place Radarweg 29, 1043 Nx Amsterdam, Netherlands
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes and Obesity (IDO)
POF-Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-501900-221
G-502200-001
G-502296-001
Grants German Center for Diabetes Research (DZD e.V.)
German Research Foundation
Neither the European Union
European Union
DOI 10.1016/j.lanepe.2024.101100
WOS ID 001371113600001
PubMed ID 39582489
Erfassungsdatum 2024-12-03
[➜Report correction]